Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Single-dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Orally Administered Pimodivir in Adult Subjects

NCT03816631 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.

NCT NCT03816631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03816631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Single-dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Orally Administered Pimodivir in Adult Subjects
Lead sponsor
Janssen-Cilag International NV
Phase
Phase 1
Overall status
Completed
Start date
May 28, 2019
Completion date
April 27, 2020
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment